Correspondence

West syndrome, can topiramate be on top?

To the Editor

In agreement with previously published studies, the study by Al-Baradie and Elseed greatly supports the notion that topiramate is generally well-tolerated and represents an effective antiepileptic drug in the treatment of West syndrome. However, the long-term safety and possible adverse effects of topiramate have not yet been fully established in infants and young children. This might halt the wide spread application of that medication in the clinical setting. Apart from poor appetite and somnolence as noticeable side effects, there are growing concerns on other potential effects of this medication in growing children, particularly the development of metabolic acidosis, disturbed bone mineral density, hypocitraturia, hypercalciuria, and elevated urine pH, leading to an increased risk of kidney stone disease. Moreover, hypohidrosis, which has not been described previously, can be clinically significant during heat stress and exercise challenge. The latter 2 potential effects, namely, the increased risk of nephrolithiasis and heat intolerance, need to be seriously considered in children on topiramate residing in countries with a hot climate like Saudi Arabia.

Mahmood D. Al-Mendalawi
Department of Pediatrics
Al-Kindy College of Medicine, Baghdad University
Baghdad, Iraq

Reply from the Author

Thank you for the comments. Topiramate is one of the new antiepileptic drugs. This novel medication will aid the improvement of the quality of life of epileptic patients through improved seizure control and reduced adverse effects. It was studied in children of various ages, ranging between 12-61 months in some of the long-term studies; confirming that topiramate represents a useful drug, effective in a wide range of seizures and epilepsy syndromes. Moreover, preliminary data seem to suggest that the efficacy of topiramate is more sustained in localization-related epilepsy than in generalized epilepsy. Although it has many side effects like any other drugs, the most common ones are drowsiness, weight loss, metabolic acidosis, kidney stones, and glaucoma, and it is very important to follow up these children carefully during the treatment, especially in areas with hot weather such as Saudi Arabia. In a study, 50 children of age 0-12 years with seizures, namely, partial seizures with or without secondary generalization, myoclonic jerks, infantile spasms, generalized tonic-clonic seizures, absence or mixed seizures were chosen from the outpatient department. Topiramate was added in small doses to conventional antiepileptics, and increased until the most effective/best-tolerated dose was reached. The authors support the efficacy and safety of topiramate as an add-on drug in seizures in children. Another prospective study demonstrated that, on the basis of primary topiramate therapy, the combination treatment of both topiramate and low-dose adrenocorticotropic hormone was effective and available for the patients with infantile spasms. Although the long-term safety and possible adverse effects of topiramate have not been fully established in infants and young children, some studies have shown that it is a useful option for children with frequent seizures unresponsive to standard anti-epileptic drugs. In general, topiramate was well tolerated. It was concluded in some studies, that topiramate is effective for a broad range of seizures in infants and young children and represents a valid therapeutic option in this population. Other new antiepileptic drugs (lamotrigine, topiramate, felbamate, and zonisamide) have shown significant efficacy in the treatment of resistant West syndrome to previous medication. The current task is to determine the risk/benefit ratios of these 2 drugs (vigabatine, adrenocorticotropic hormone) and to delineate the group of patients with West syndrome where their use would be optimal.

Raidah S. Al-Baradie
Department of Pediatrics, Dammam University and the Neuroscience Center, King Fahd Specialist Hospital Dammam, Saudi Arabia

References


---

**Do you have any comments or questions?**

**Agree or disagree with published articles?**

The correspondence section within the articles is a forum to comment on any of the articles published in the journal. Correspondence will not be sent for peer review, and will only be edited for the use of appropriate language. All correspondence should be submitted and published within 6 months from the date of the original publication.

Please submit your correspondence through the journal website (www.neurosciencesjournal.org), and don’t forget to clearly state the title of the original publication, and your contact details.